Per Norlén (Alligator Bioscience AB (Nasdaq Stockholm: ATORX))

Norlén, Per (Alligator Bioscience –202103 CEO)

	Organisation	Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
	Group	Alligator Bioscience (Group)
	Product	mitazalimab (ADC-1013)
	Product 2	ALG.APV-527 (Alligator Bioscience / Aptevo Therapeutics)

Record changed: 2021-03-18

More documents for Per Norlén

[1] Alligator Bioscience AB. (3/18/21). "Press Release: Alligator Bioscience Appoints Søren Bregenholt as New CEO". Lund....
[2] Alligator Bioscience AB. (2/12/20). "Press Release: Alligator Bioscience AB Year-end Report January-December 2019"....
[3] Alligator Bioscience AB. (12/17/19). "Press Release: First Patient Dosed with ATOR-1017 Developed for Metastasized Cancer". Lund....
[4] Alligator Bioscience AB. (12/11/19). "Press Release: CFO Per-Olof Schrewelius Leaves Alligator Bioscience". Lund....
[5] Alligator Bioscience AB. (11/29/19). "Press Release: Alligator Bioscience AB Appoints Chief Operating Officer". Lund....
[6] Alligator Bioscience AB. (8/20/19). "Press Release: Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.". Lund....
[7] Alligator Bioscience AB. (7/31/19). "Press Release: Alligator Bioscience Regains Global Rights from Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)". Lund....
[8] Alligator Bioscience AB. (1/7/19). "Press Release: Alligator Bioscience Launches RUBY, a Novel Concept in Bispecific Antibody Formats". Lund....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]